



PerkinElmer Highlights New Drug Discovery and Life Science Research Solutions at the Society for Biomolecular Sciences (SBS) 2011 Conference

ORLANDO, FL –At the [Society for Biomolecular Sciences 2011](#) in Orlando, Florida, [PerkinElmer, Inc.](#), a global leader focused on the health and safety of people and the environment, will be showcasing several new drug discovery technologies and applications - including new products based on [Alpha technology](#) and a novel panel of epigenetics-based detection reagents.

According to Martina Bielefeld-Sévigny, Ph.D., vice president and general manager, Drug Discovery and Research Reagent Solutions, Bio-discovery, PerkinElmer, “PerkinElmer provides researchers in drug discovery and life sciences with the ability to approach targets from multiple perspectives; to locate, detect and quantify their targets of interest, to analyze and understand them in wider physiological contexts. Our ability to deliver reagents, instruments, knowledge and services, helps advance research and drug discovery with the translational data and analysis to help lead to breakthrough insights.”

PerkinElmer's SBS offerings will include the Company's expanded epigenetic detection reagents specifically validated for drug discovery and life sciences research for disease states including cancer, neurodegenerative and metabolic disorders, as well as applications for stem cells and immunology. Additionally, PerkinElmer will also feature the [EnSpire® Multimode Plate Reader](#) with new optical label-free detection, the first and only benchtop detection platform to combine Corning® Epic® label-free technology and traditional labeled assays to accurately identify and characterize potential new therapeutic targets. This combination of labeled and label-free detection technologies provides researchers with a more complete and insightful view of their cellular and biochemical interactions.

PerkinElmer's new technologies and assay expansions on display at SBS Booth 701 include:

- [EnSpire Multimode Plate Reader](#) with label-free technology
- [Expanded target class coverage for Epigenetics](#), cellular kinases and protein-protein interactions
- [Expansion of the AlphaLISA® research assays](#) to over 100 no-wash biomarker kits for a variety of therapeutic areas including neurodegeneration, cancer and virology
- [Operetta® High Content Imaging System](#) with new PhenoLOGIC™, machine learning technology for intuitive cell classification

PerkinElmer's epigenetic and post-DNA translational screening tools now cover nine different histone marks as well as p53, with more than 15 validated enzyme assays to help researchers discover novel drug compounds directed against several epigenetic enzymes, such as histone methyltransferases (HMTs), demethylases (HDMs), acetyltransferases (HATs) and deacetylases (HDACs).

Additional PerkinElmer products on display at SBS Booth 701 will include:

- [FMT in vivo Imaging System](#)
- [Operetta® High Content Imaging System](#)
- [Columbus® Data Management Software](#)
- [Volocity® 3D Imaging Software](#)
- [EnVision® Multilabel Plate Reader](#)
- [JANUS® Automated Workstation](#)

PerkinElmer's Full Day Interactive Workshop

[Well to Cell and Beyond - Widen the Physiological Perspective](#)

Sunday, March 27, 9:00 a.m. – 4:30 p.m., Gaylord Palms Resort and Convention Center, Naples Room (*Complimentary lunch included*)

Join colleagues from pharmaceutical discovery and academia to learn about experiences with emerging technologies used for studying the cell signaling continuum in entirely new ways. A series of user presentations will offer an overview of leading

solutions and novel techniques being applied to aid in the future of cellular biological research.

Presentations include:

- ***Automated object-level feature extraction, classification and display: procedures in Acapella® for high-content analysis***
9:15 a.m. – 10:00 a.m. - Jarkko Ylaanko, McMaster University, Toronto
- ***Detection and quantification of multinucleated cells as a measure of INCENP phenotypic penetrance***
10:00 a.m. – 10:45 a.m. - Hind Azegrouza, Ph.D., CNIC, Madrid, Spain
- ***Development of direct acting inhibitors of epigenetic reader proteins***
1:45 p.m. – 2:30 p.m. - Michael McKeown, Dana Farber Cancer Institute
- ***Applications in Epigenetics: labeled and label free detection***
2:45 p.m. – 3:30 p.m. - William Janzen, UNC Eshelman School of Pharmacy
- ***Known and Unknown: Potential of unbiased label-free cellular assays in drug discovery***
3:30 p.m. – 4:15 p.m.- Charles Lunn, Ph.D., Merck Research Laboratories

For more information about the PerkinElmer offerings at SBS, including in-booth education, customer workshops, technical posters and presentations, visit www.perkinelmer.com/SBS2011.

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately \$1.7 billion in 2010, has about 6,200 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

Media Contacts:

Amanda L. Connolly
Edelman (On behalf of PerkinElmer, Inc.)
Phone: (404) 832-6785
Email: amanda.connolly@edelman.com